Key Drivers
- Profit rebound
- Leverage rising
- Cash positive
AIAI Summary
TFX should now be viewed less as a headline growth story and more as a portfolio-cleanup/capital-return play: the OEM divestiture and buybacks improve flexibility, but with core constant-currency growth only ~4.7% and leverage still elevated, the stock's upside depends on management converting a cleaner mix into durable self-funded earnings growth rather than just financial engineering.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profit rebound
- •Leverage rising
- •Cash positive
TFX's FY2025 was कमजोर overall with a large net loss despite solid gross margins, but the latest quarter showed strong profitability and cash flow, leaving leverage and trailing valuation as the main risks.
Price Behavior
Key Price Behavior Insights:
- •Holding Support
- •Failed Breakout
- •Range Recovery
TFX remains mildly constructive, trading slightly above its last month average and holding key support near $133, but it still needs a break above $140 to confirm a stronger upmove.
Failed move to $140.12 was followed by a sharp drop to $133.00, showing weak breakout momentum
Sentiment & News
Key News Insights:
- •Q2 Revenue Beat
- •OEM Sale Closed
- •Integration Lag
Teleflex posted strong Q2 revenue growth and key strategic wins, but integration issues in its acquired vascular business and ongoing portfolio reshaping keep execution risk in focus.
The news is mildly positive overall, as strong growth and strategic simplification are offset by near-term integration challenges
Similar Companies in Healthcare
Other companies in the same sector with AI ratings